| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.37 | 6e-13 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.32 | 2e-09 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.31 | 1e-08 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.17 | 6e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.28 | 6e-06 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-05 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-05 |